Novelos touts promising initial results for agent LIGHT

04/26/2012 | Yahoo!

Novelos Therapeutics said the University of Wisconsin Carbone Cancer Center has finished the first cohort in a Phase I/II trial involving I-124-CLR1404, its PET imaging agent for cancer that is being tested on patients with advanced non-small cell lung cancer. Initial study results indicate the agent, also called LIGHT, can identify tumors more accurately than 18F-fluorodeoxyglucose, a researcher said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX